ITRMIterum Therapeutics plc

Nasdaq iterumtx.com


$ 1.58 $ -0.03 (-1.9 %)    

Friday, 03-May-2024 14:46:03 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 1.55
$ 1.58
$ 0.00 x 0
$ 0.00 x 0
$ 1.58 - $ 1.58
$ 0.62 - $ 2.50
46,917
na
20.09M
$ 1.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-28-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 03-25-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

 on-april-3-iterum-therapeutics-received-letter-from-nasdaq-indicating-that-it-is-not-in-compliance-with-nasdaq-listing-rule

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

 update-iterum-therapeutics-q4-adjusted-eps-081-beats-094-estimate

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...

 iterum-therapeutics-q4-adj-eps-081-beats-093-estimate

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

 iterum-therapeutics-provides-updates-expects-to-resubmit-new-drug-application-for-oral-sulopenem-to-fda-earlier-than-original-planned

Resubmission of NDA is On Track for First Half of Q2 24

 hc-wainwright--co-upgrades-iterum-therapeutics-to-buy-maintains-price-target-to-6

HC Wainwright & Co. analyst Ed Arce upgrades Iterum Therapeutics (NASDAQ:ITRM) from Neutral to Buy and maintains the pri...

 why-iterum-therapeutics-stock-is-trending-today

Iterum Therapeutics announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Res...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION